TD Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$853M Sell
3,920,076
-240,440
-6% -$53.3M 0.69% 35
2025
Q4
$951M Sell
4,160,516
-97,811
-2% -$22.3M 0.76% 29
2025
Q3
$986M Buy
4,258,327
+522,512
+14% +$106M 0.8% 26
2025
Q2
$693M Buy
3,735,815
+512,440
+16% +$95.2M 0.59% 35
2025
Q1
$675M Buy
3,223,375
+531,156
+20% +$103M 0.62% 34
2024
Q4
$478M Sell
2,692,219
-1,002,561
-27% -$184M 0.42% 49
2024
Q3
$720M Buy
3,694,780
+144,260
+4% +$26.9M 0.64% 31
2024
Q2
$609M Buy
3,550,520
+76,500
+2% +$12.7M 0.57% 38
2024
Q1
$633M Buy
3,474,020
+2,116,997
+156% +$365M 0.59% 36
2023
Q4
$210M Buy
1,357,023
+221,463
+20% +$32.3M 0.21% 93
2023
Q3
$169M Buy
1,135,560
+35,481
+3% +$5.21M 0.21% 89
2023
Q2
$148M Sell
1,100,079
-6,001
-0.5% -$880K 0.17% 108
2023
Q1
$176M Buy
1,106,080
+197,090
+22% +$30.1M 0.21% 92
2022
Q4
$147M Buy
908,990
+5,154
+0.6% +$790K 0.18% 110
2022
Q3
$129M Sell
903,836
-30,330
-3% -$4.35M 0.16% 110
2022
Q2
$143M Sell
934,166
-36,809
-4% -$5.62M 0.17% 110
2022
Q1
$157M Sell
970,975
-40,548
-4% -$5.89M 0.14% 128
2021
Q4
$137M Sell
1,011,523
-21,813
-2% -$2.58M 0.11% 154
2021
Q3
$111M Sell
1,033,336
-19,140
-2% -$2.19M 0.12% 138
2021
Q2
$122M Sell
1,052,476
-53,189
-5% -$5.99M 0.12% 140
2021
Q1
$120M Buy
1,105,665
+40,649
+4% +$4.35M 0.13% 128
2020
Q4
$114M Buy
1,065,016
+53,124
+5% +$5.11M 0.14% 135
2020
Q3
$88.6M Buy
1,011,892
+136,853
+16% +$12.9M 0.12% 148
2020
Q2
$85.9M Buy
875,039
+26,083
+3% +$2.3M 0.12% 144
2020
Q1
$64.7M Buy
848,956
+88,535
+12% +$7.54M 0.11% 154
2019
Q4
$67.3M Buy
760,421
+48,226
+7% +$4M 0.1% 175
2019
Q3
$53.9M Buy
712,195
+86,817
+14% +$5.95M 0.08% 201
2019
Q2
$45.5M Buy
625,378
+6,931
+1% +$545K 0.07% 221
2019
Q1
$49.8M Sell
618,447
-109,152
-15% -$8.93M 0.08% 205
2018
Q4
$67.1M Sell
727,599
-3,386
-0.5% -$298K 0.12% 148
2018
Q3
$69.1M Sell
730,985
-51,946
-7% -$4.93M 0.1% 168
2018
Q2
$72.5M Sell
782,931
-786,899
-50% -$76.9M 0.11% 157
2018
Q1
$149M Sell
1,569,830
-1,162,019
-43% -$128M 0.23% 84
2017
Q4
$264M Sell
2,731,849
-68,742
-2% -$6.48M 0.38% 49
2017
Q3
$249M Sell
2,800,591
-55,811
-2% -$4.25M 0.37% 52
2017
Q2
$207M Sell
2,856,402
-64,139
-2% -$4.31M 0.33% 56
2017
Q1
$190M Buy
2,920,541
+57,134
+2% +$3.59M 0.3% 62
2016
Q4
$179M Buy
2,863,407
+42,673
+2% +$2.6M 0.3% 61
2016
Q3
$178M Buy
2,820,734
+31,728
+1% +$2.05M 0.31% 63
2016
Q2
$173M Sell
2,789,006
-839,060
-23% -$51.1M 0.31% 64
2016
Q1
$207M Sell
3,628,066
-529,994
-13% -$29.5M 0.39% 50
2015
Q4
$246M Buy
4,158,060
+282,852
+7% +$16.3M 0.49% 42
2015
Q3
$211M Sell
3,875,208
-93,280
-2% -$6.07M 0.42% 47
2015
Q2
$267M Buy
3,968,488
+1,348,953
+51% +$88.1M 0.48% 42
2015
Q1
$153M Buy
2,619,535
+1,104,183
+73% +$66.7M 0.28% 67
2014
Q4
$99.2M Buy
1,515,352
+115,245
+8% +$7.27M 0.17% 116
2014
Q3
$80.9M Buy
1,400,107
+110,957
+9% +$6.16M 0.14% 128
2014
Q2
$72.8M Buy
1,289,150
+1,147
+0.1% +$60.2K 0.12% 136
2014
Q1
$66.2M Sell
1,288,003
-119,407
-8% -$6.03M 0.12% 141
2013
Q4
$74.3M Sell
1,407,410
-36,999
-3% -$1.82M 0.14% 131
2013
Q3
$64.6M Buy
1,444,409
+52,867
+4% +$2.34M 0.13% 135
2013
Q2
$57.5M Buy
+1,391,542
New +$60.9M 0.12% 135

Other funds holding ABBV

TD Asset Management's ABBV Position: Q1 2026 in Review

TD Asset Management reduced its AbbVie (ABBV) stake by 5.8% in Q1 2026, selling an estimated $53.3M and leaving 3,920,076 shares worth $853M. The position accounts for 0.69% of the portfolio, ranked #35.

TD Asset Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $986M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • TD Asset Management held 3,920,076 shares of AbbVie worth $853M as of Q1 2026.
  • TD Asset Management sold 240,440 AbbVie shares in Q1 2026, an estimated $53.3M.
  • AbbVie made up 0.69% of TD Asset Management's portfolio in Q1 2026, its #35 holding.
  • TD Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • TD Asset Management's AbbVie position peaked at $986M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.